Literature DB >> 10653222

Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline.

J S Markowitz, C L DeVane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10653222     DOI： 10.1097/00004714-200002000-00023

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  9 in total

1.  Significant reduction of sertraline plasma levels by carbamazepine and phenytoin.

Authors:  Maria Pihlsgård; Erik Eliasson
Journal:  Eur J Clin Pharmacol       Date:  2002-02       Impact factor: 2.953

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

Review 4.  Clinical pharmacokinetics of sertraline.

Authors:  C Lindsay DeVane; Heidi L Liston; John S Markowitz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression.

Authors:  Guillermo Cáceres; Rodrigo Calderon; Cesar Ugarte-Gil
Journal:  Ther Adv Infect Dis       Date:  2022-05-20

Review 6.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment.

Authors:  Siobhan Gee; Thomas Dixon; Mary Docherty; Sukhwinder S Shergill
Journal:  BMC Psychiatry       Date:  2015-08-12       Impact factor: 3.630

8.  Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.

Authors:  Joshua Rhein; Bozena M Morawski; Kathy Huppler Hullsiek; Henry W Nabeta; Reuben Kiggundu; Lillian Tugume; Abdu Musubire; Andrew Akampurira; Kyle D Smith; Ali Alhadab; Darlisha A Williams; Mahsa Abassi; Nathan C Bahr; Sruti S Velamakanni; James Fisher; Kirsten Nielsen; David B Meya; David R Boulware
Journal:  Lancet Infect Dis       Date:  2016-03-10       Impact factor: 25.071

9.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.